Migraine with Aura and Hormonal Contraception — A Safety and Documentation Priority
Migraine with aura plus combined hormonal contraceptives multiplies stroke risk approximately four to eight times — WHO Category 4 requires switching to progestin-only or non-hormonal methods.
PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.
The core risk. Migraine with aura independently increases ischemic stroke risk approximately two-fold. Combined hormonal contraceptives (CHCs) containing estrogen also independently increase stroke risk. Together, the effect is multiplicative — not additive — producing approximately 4 to 8 times baseline stroke risk. For a 30-year-old woman, the absolute risk remains low but is clinically significant and entirely avoidable.
What the guidance requires. The WHO Medical Eligibility Criteria (5th edition) categorizes combined hormonal contraceptive use in migraine with aura as Category 4 — risks outweigh benefits, and the method should not be used. This applies regardless of aura frequency, severity, or age; the aura diagnosis alone is sufficient. If the patient is currently on a CHC and reports any aura symptoms, discontinue the CHC and switch to a progestin-only or non-hormonal method. Document the assessment and the change.
Migraine subtype and triptan contraindications. Hemiplegic migraine — where aura includes motor weakness — and migraine with brainstem aura are absolute contraindications to triptan use per FDA labeling. No clinical argument overrides this. For these patients, gepants (ubrogepant, rimegepant, zavegepant) or lasmiditan are the acute treatment options.
Ready to run a PA?
The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.
Run a PA — free →Citations: WHO Medical Eligibility Criteria for Contraceptive Use, 5th ed. (2015) — who.int/publications/i/item/9789241549158 | MacClellan LR et al., BMJ 2007;334(7599):880 (stroke risk data) | AHS Consensus 2021 — Ailani J et al., Headache 2021;61(7):1021-1039. doi:10.1111/head.14153 | FDA triptan labeling (hemiplegic/brainstem aura contraindication).